Razor Genomics

Razor Genomics, founded in 2009 and based in Nashville, TN, has developed and commercialized the RiskReveal™ molecular stratification test for early-stage, non-squamous NSCLC. The test analyzes a 14-gene signature from tumor tissue to predict recurrence risk, with clinical evidence suggesting it outperforms standard clinicopathological criteria in identifying high-risk patients. By providing a more precise risk assessment, Razor Genomics seeks to address a critical unmet need in the post-surgical management of lung cancer, potentially enabling personalized adjuvant therapy decisions to improve survival rates. The company operates as a commercial-stage diagnostics provider, offering the test through an out-of-network billing model with patient assistance programs.

14-gene expression signature analyzed via qPCR from FFPE tumor tissue to generate a molecular risk score for recurrence in early-stage NSCLC.

RiskReveal competes in the molecular prognostic test space for early-stage NSCLC. Direct competitors include Myriad Genetics' myPlan® Lung Cancer test and the Oncotype DX® Lung RS test, which also provide recurrence risk scores. The broader competitive set includes clinicopathological criteria (NCCN guidelines) and emerging circulating tumor DNA (ctDNA) assays for minimal residual disease detection, which are gaining traction for post-surgical risk assessment.